|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||117.66 - 119.51|
|52 Week Range||102.78 - 141.95|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||19.44|
|Forward Dividend & Yield||2.97 (2.53%)|
|Ex-Dividend Date||Apr 11, 2022|
|1y Target Est||127.50|
Subscribe to Yahoo Finance Plus to view Fair Value for NSRGY
Ah, nuts. They should've stuck to Baby Ruths and Butterfingers. Nestlé announced Tuesday it will unload the world's only approved peanut...
Palforzia, the world’s only approved peanut allergy drug, has so far proved a flop, potentially because of a laborious treatment process.
Nestlé’s shareholders prefer sugary stuff in the form of capital gains and payouts. Chief executive Mark Schneider has therefore soured the mood with the news of the bite inflation has taken out of the Swiss food company’s profitability. Global inflation may moderate next year.